BCX17725
Netherton Syndrome
Pre-Clinical/Phase 1Investigational
Key Facts
Indication
Netherton Syndrome
Phase
Pre-Clinical/Phase 1
Status
Investigational
Company
About BioCryst Pharmaceuticals
Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| QRX003 | Quoin Pharmaceuticals | Phase 3 |
| ATR-12 | Azitra | Phase 1 |